AI Creators
Peter Diamandis (Moonshots - AI playlist)
David Sinclair on the Longevity Pill, Age Reversal Timelines, and Updated Protocols | EP #249
Apr 27, 2026
Key Points
- 1.David Sinclair is about to begin the first human trial for epigenetic reprogramming to cure blindness.
- 2.The research uses a subset of Yamanaka genes, showing promise for reversing aging across various body tissues.
- 3.Future applications may include treatments for ALS, memory improvement, and overall longevity.
Summary
First Human Trial of Epigenetic Reprogramming
David Sinclair is launching the first human trial for a drug candidate developed in his lab, which involves epigenetic reprogramming to potentially cure blindness. The trial will apply three Yamanaka genes in a patient's eye, a significant step in the fight against age-related diseases.
Broad Applications of Yamanaka Genes
The Yamanaka genes employed in the study may have effects that extend beyond just curing blindness. Preliminary animal studies indicate potential age reversal benefits in various tissues, including improvements in memory, motor neuron function, and muscle health.
Future Direction and Safety Considerations
While the eye was chosen for initial trials, Sinclair suggests the liver may be the next target for these therapies. The approach is cautious, focusing on one tissue at a time to satisfy FDA regulations, but future applications could see broader interventions as more safety data becomes available.
Worth watching for
This video is for individuals interested in breakthroughs in longevity science and epigenetic technologies.